5:39 PM
 | 
Apr 30, 2013
 |  BC Extra  |  Company News

Delcath falls after FDA reviewers question Melblez Kit safety

Delcath Systems Inc. (NASDAQ:DCTH) fell $0.56 (40%) to $0.83 on Tuesday after FDA reviewers said the company's Melblez Kit chemosaturation system, which delivers melphalan to treat unresectable ocular...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >